How Non-invasive Visible Light Imaging Can Change Drug Discovery Dr Peter Lassota and Dr Anjani Shah In the past decade, non-invasive visible light imaging gained acceptance not only as a valuable research tool, but also as a means of evaluating new compounds for efficacy and pharmacodynamic properties in drug discovery. Read More
Monochromator vs Filter-based Plate Readers By Dr John Comley This article is based around feedback obtained in HTStec's recent Multi-Mode Microplate Reader Trends 2007 Report. It highlights findings on what influences reader choice, current use of different plate reader detection modalities, main target types/classes investigated using plate readers, sources of… Read More
Technology, Bane or Bonanza for the Pharmaceutical industry? By Dr Stephen Naylor, Adam W. Culbertson and Dr Stephen J. Valentine Productivity in the pharmaceutical industry has long held well-documented concerns. While the adoption of new technologies into the drug discovery and development process has often been seen as a… Read More
Reshaping the Landscape of Cancer Drug Discovery and Development By Dr Paolo Paoletti The landscape of cancer drug discovery and development is shifting, adjusting and reshaping itself in response to the huge rush of scientific knowledge which has come to the fore over the past few decades. In collaboration with… Read More
By Dr Jean-Luc Vanderheyden As the experience and advances in Positron Emission Tomography (PET) imaging grows, so does the belief that this technology can have a key role to play in ushering in an era of personalised medicine while also offering an enormous contribution in reducing the attrition rates in… Read More
The Role of Repositioning in Drug Discovery and Development By Dr Louis A. Tartaglia and Dr Lee E. Babiss The large number of drug candidate failures in recent years has been enormously costly for the pharmaceutical industry, but has also created the tremendous opportunity of repositioning these molecules into new… Read More
Ultra-sensitive measurement of protein and nucleic acid biomarkers may enable earlier disease detection and more effective therapies By Dr Gregory Shipp The pharmaceutical industry is striving to develop effective new therapies for diseases, ranging from cancers to cardiovascular and neurodegenerative disorders to a host of metabolic, infectious and genetic conditions,… Read More
Zebrafish: a versatile in vivo model for drug safety assessment Dr Wendy Alderton and Dr St phane Berghmans Safety pharmacology has become an integral part of non-clinical safety assessment for new chemical entities in the past two decades (1). The relative novelty of this discipline has granted it the flexibility… Read More
Kinase Inhibitor Screening - Latest technologies and techniques By Dr Richard M. Eglen and Dr Roger Bossé Kinases have become a proven target class for new drugs and have created a thirst for the development of new technology platforms for inhibitor detection. We discuss some of the latest technologies and… Read More
Confocal vs Widefield High Content Imaging By Dr John Comley A variety of new confocal hardware and software solutions have recently become available to support high content imaging. Most of the solutions have in common the potential of rejecting out-of-focus background fluorescence and of improving the signal to noise of… Read More
Miniaturisation of Assay Development and Screening By Andreas Boettcher and Dr Lorenz M. Mayr In recent years we have seen a strong increase in the number of chemical compounds and molecular targets used for lead discovery by high-throughput screening among most Pharma and Biotech companies. This has caused a strong… Read More
Current Biosensor Technologies in Drug Discovery By Dr Matthew A. Cooper Over the past two decades the benefits of biosensor analysis have begun to make an impact in the market, and systems are beginning to be used as mainstream research tools in many laboratories. Biosensors are devices that use biological… Read More
Changing Dynamics in Dispense and Imaging Assays By Dr John Comley The prospects for a significant shift in dispense and imaging (D&I) assays towards a greater utilisation of calcium-mediated flash luminescence readouts appears to be finally under way. Driving this changing dynamic is the acceptance that assay sensitivity (better quality… Read More
PLAYING WITH TIME – Digital imaging comes of age By Dr Pam Pickering Seeing dynamic intra- and extra-cellular events as they happen is central to revealing the mechanisms of disease, identifying key targets for drug intervention and assessing the impact of drug treatment on living cells. Interpreting these events through… Read More
By Dr Amarpreet S Dhiman In terms of drug discovery and development, the role of nanotechnology currently lies in improving diagnostic methods, developing improved drug formulations and drug delivery systems for disease therapy. The breakthrough format of nanotechnology offers innovative solutions, giving researchers greater analytical capacity, improved data quality and… Read More
Share Share Tweet Email Understanding the strategic importance of BIOMARKERS for the discovery and early development phases Understanding the strategic importance of BIOMARKERS for the discovery and early development phases By Dr Orest Hurko Biomarkers have become an increasingly hot topic in the pharmaceutical industry. How much of this is… Read More